Global Myeloproliferative Disorders Drugs Market to Reach $9.9 Billion by 2027
Amid the COVID-19 crisis, the global market for Myeloproliferative Disorders Drugs estimated at US$7.8 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at a CAGR of 3.4% over the period 2020-2027. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is projected to record 3.2% CAGR and reach US$7.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ph- Myeloproliferative Neoplasms (MPNs) segment is readjusted to a revised 4.1% CAGR for the next 7-year period.
The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 5.4% CAGR
The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 5.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.
Select Competitors (Total 34 Featured):
Amid the COVID-19 crisis, the global market for Myeloproliferative Disorders Drugs estimated at US$7.8 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at a CAGR of 3.4% over the period 2020-2027. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is projected to record 3.2% CAGR and reach US$7.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ph- Myeloproliferative Neoplasms (MPNs) segment is readjusted to a revised 4.1% CAGR for the next 7-year period.
The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 5.4% CAGR
The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 5.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.
Select Competitors (Total 34 Featured):
- Bristol-Myers Squibb
- Inctye
- Novartis
- Pfizer
- Takeda
- Teva
Note: Product cover images may vary from those shown
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Impact of Covid-19 and a Looming Global Recession
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 2: World Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 3: World 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
- Table 4: World Current & Future Analysis for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 5: World Historic Review for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 6: World 15-Year Perspective for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- Table 7: World Current & Future Analysis for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 8: World Historic Review for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 9: World 15-Year Perspective for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- UNITED STATES
- Table 10: USA Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 11: USA Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 12: USA 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- CANADA
- Table 13: Canada Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 14: Canada Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 15: Canada 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- JAPAN
- Table 16: Japan Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 17: Japan Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 18: Japan 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- CHINA
- Table 19: China Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 20: China Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 21: China 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- EUROPE
- Table 22: Europe Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 23: Europe Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 24: Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
- Table 25: Europe Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 26: Europe Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 27: Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- FRANCE
- Table 28: France Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 29: France Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 30: France 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- GERMANY
- Table 31: Germany Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 32: Germany Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 33: Germany 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- ITALY
- Table 34: Italy Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 35: Italy Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 36: Italy 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- UNITED KINGDOM
- Table 37: UK Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 38: UK Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 39: UK 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- SPAIN
- Table 40: Spain Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 41: Spain Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 42: Spain 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- RUSSIA
- Table 43: Russia Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 44: Russia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 45: Russia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- REST OF EUROPE
- Table 46: Rest of Europe Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 47: Rest of Europe Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 48: Rest of Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- ASIA-PACIFIC
- Table 49: Asia-Pacific Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 50: Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 51: Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
- Table 52: Asia-Pacific Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 53: Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 54: Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- AUSTRALIA
- Table 55: Australia Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 56: Australia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 57: Australia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- INDIA
- Table 58: India Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 59: India Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 60: India 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- SOUTH KOREA
- Table 61: South Korea Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 62: South Korea Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 63: South Korea 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- REST OF ASIA-PACIFIC
- Table 64: Rest of Asia-Pacific Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 65: Rest of Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 66: Rest of Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- LATIN AMERICA
- Table 67: Latin America Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 68: Latin America Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 69: Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
- Table 70: Latin America Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 71: Latin America Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 72: Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- ARGENTINA
- Table 73: Argentina Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 74: Argentina Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 75: Argentina 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- BRAZIL
- Table 76: Brazil Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 77: Brazil Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 78: Brazil 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- MEXICO
- Table 79: Mexico Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 80: Mexico Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 81: Mexico 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- REST OF LATIN AMERICA
- Table 82: Rest of Latin America Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 83: Rest of Latin America Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 84: Rest of Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- MIDDLE EAST
- Table 85: Middle East Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 86: Middle East Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 87: Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
- Table 88: Middle East Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 89: Middle East Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 90: Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- IRAN
- Table 91: Iran Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 92: Iran Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 93: Iran 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- ISRAEL
- Table 94: Israel Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 95: Israel Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 96: Israel 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- SAUDI ARABIA
- Table 97: Saudi Arabia Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 98: Saudi Arabia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 99: Saudi Arabia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- UNITED ARAB EMIRATES
- Table 100: UAE Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 101: UAE Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 102: UAE 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- REST OF MIDDLE EAST
- Table 103: Rest of Middle East Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 104: Rest of Middle East Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 105: Rest of Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- AFRICA
- Table 106: Africa Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 107: Africa Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 108: Africa 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 & 2027
- Total Companies Profiled: 34
Note: Product cover images may vary from those shown